Executive officer

Jason K. Garland

Chief Financial Officer·Repligen Corp.

About

Jason K. Garland joined Repligen in September 2023 as the CFO, where he oversees financial operations for the Company, including all corporate finance and audit functions, capital markets and M&A transactions, financial planning and analysis, budgeting, financial risk management, information technology and investor relations.

Mr. Garland was previously with Integer Holdings Corporation, a medical device outsource manufacturer, where he served for nearly five years as Executive Vice President and CFO. Prior to Integer, he spent three years as Vice President and CFO for the global sales and supply divisions of Tiffany & Co., following nearly 20 years of increasing responsibility at General Electric Corporation, culminating in his role as CFO for GE Industrial Solutions, then a multi-billion dollar business with over 40 manufacturing sites.

Mr. Garland served on the board of directors and was Audit Committee Chair for Acutus Medical, a publicly-traded medical device company, from 2022 to 2025. He holds a B.S. in Chemical Engineering from the University of New Hampshire, and is Lean Six Sigma Black Belt certified.

Since 2023
Age 52
Tenure 3 yrs

Also at Repligen Corp.

OL Olivier Loeillot President and Chief Executive Officer, Director MM Martin D. Madaus Director, Chair of the Board KD Karen A. Dawes Director NB Nicolas M. Barthelemy Director CM Carrie Eglinton Manner Director KK Konstantin Konstantinov Director

Roles

Organization Role Dates Details
Repligen Corp. Chief Financial Officer 2023–present Current role
Integer Holdings Corporation Executive Vice President and CFO Medical device outsource manufacturer; nearly five years.
Tiffany & Co. Vice President and CFO, global sales and supply divisions Three years.
General Electric Corporation CFO, GE Industrial Solutions Nearly 20 years of increasing responsibility at GE; GE Industrial Solutions was a multi-billion dollar business with over 40 manufacturing sites.

External roles

Organization Role Dates
Acutus Medical Director and Audit Committee Chair (former) 2022-2025

Related

Source: Repligen Corp. proxy statement (SEC Schedule 14A)

Where the filing does not disclose a value, this page states "Not disclosed" rather than estimating. Smaller filers are exempt from disclosing metric targets and achievement, and larger filers may omit forward targets for competitive reasons.

See how VectorShift works for your firm

Request Demo